Natera Published Personalized And Tumor-informed Molecular Residual Disease Test, Signatera, To Detect Recurrence Early In Patients With Early-Stage Breast Cancer In JCO Precision Oncology
Natera Published Personalized And Tumor-informed Molecular Residual Disease Test, Signatera, To Detect Recurrence Early In Patients With Early-Stage Breast Cancer In JCO Precision Oncology
Natera發佈了個性化且以腫瘤爲依據的分子殘留疾病測試Signatera，用於在JCO Precision Oncology中及早發現早期乳腺癌患者的復發
Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer
擴大了EBLIS研究，對所有乳腺癌亞型進行了長達12年的臨床隨訪
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。